Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  ovarian serous cystadenocarcinoma
Stage/Subtype:  ovarian serous cystadenocarcinoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 30 for your search:
Start Over
Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: GOG-0281, NCI-2014-00629, NCT02101788
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY005, NCI-2015-00651, NCT02502266
Pegylated Liposomal Doxorubicin Hydrochloride with Atezolizumab and/or Bevacizumab in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Not yet active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY009, NCI-2016-01081, NCT02839707
MV-NIS Infected Mesenchymal Stem Cells in Treating Patients with Recurrent Ovarian Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1266, NCI-2014-00016, NCT02068794
Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AL3818-US-001, NCI-2015-01926, NCT02558348
Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3000-PN162-01-001, NCI-2016-00219, NCT02657889
Olaparib and Tremelimumab in Treating BRCA1 or BRCA2 Mutation Carrier Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 99
Trial IDs: INST 1419, NCI-2016-00434, NCT02571725
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients with Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY007, NCI-2016-00203, NCT02713386
Nintedanib in Treating Patients with Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Previously Treated with Bevacizumab
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00033060, NCI-2013-00455, NCT01669798
Surgery with or without Carboplatin in Treating Patients with Recurrent Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 21
Trial IDs: 12-275, NCI-2013-00405, NCT01767675
Enzalutamide in Treating Patients with Advanced or Recurrent Androgen Receptor-Positive Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-119, NCI-2013-02217, NCT01974765
Gemcitabine Hydrochloride with or without WEE1 Inhibitor MK-1775 in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9568, NCI-2014-00620, NCI 9568, NCT02151292, PHL-093, NCT02101775
Metformin Hydrochloride and Combination Chemotherapy in Treating Patients with Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 77
Trial IDs: IRB13-1235, NCI-2014-00860, UC IRB13-1235, NCT02122185
LY2606368 in Treating Patients with BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple-Negative Breast Cancer, High Grade Ovarian Cancer, or Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0156, NCI-2014-02304, 140156, 342996, P131428, NCT02203513
Olaparib and Cediranib Maleate in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9825, NCI-2015-00051, 16-700, NCT02345265
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients with Ovarian, Fallopian, or Peritoneal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1365, NCI-2015-00133, NCT02364713
Gemcitabine Hydrochloride Alone or with VX-970 in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9944, NCI-2015-01910, NCT02595892
Carboplatin and Gemcitabine Hydrochloride with or without ATR Kinase Inhibitor VX-970 in Treating Patients with Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1563, NCI-2015-02064, 9948, NCT02627443
Effect of Acetylcysteine with Topotecan Hydrochloride on the Tumor Microenvironment in Patients with Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15P.404, NCI-2015-01564, 2015-005, 2405, NCT02569957
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1609, NCI-2016-01041, NCT02834013
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: I 270715, NCI-2016-00534, NCT02853318
TPIV200 and Durvalumab in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-011, NCI-2016-01539, NCT02764333
Buparlisib or Alpelisib and Olaparib in Treating Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-159, NCI-2012-01929, CBKM120ZUS32T, ISS22810064, NCT01623349
Start Over